While the human papilloma virus (HPV) vaccine was first designed to prevent cervical cancer, its role in cancer prevention has expanded to cover six types of cancer. Most recently, the FDA approved the HPV vaccine to prevent oropharyngeal and other head and neck cancers. Explore the expanded benefits of the HPV vaccines and the impact these changes have on vaccine recommendations.
The HPV Vaccine: Moving Beyond Teenage Populations
The human papillomavirus (HPV) vaccination, first introduced in the U.S. more than 10 years ago, was designed to protect young women from cervical cancer. Since that time, the Centers for Disease Control & Prevention (CDC) reports that HPV cancers and genital warts have decreased by 71% among teen girls. The vaccine’s success has led to research identifying new opportunities for protection against HPV among other patient populations that can help further drive down infection rates.
Adding Vaccines to the Back-To-School List
Improving Cancer Prevention in Youth Through Vaccines
Calling For Support: Recommend the HPV Vaccine
It’s been nearly 10 years since the CDC first recommended immunization against human papillomavirus (HPV), the disease known to cause many types of gynecological and reproductive cancers. During that time, numerous studies have supported the vaccine’s efficiency. Yet through a decade of endorsements and advancements, the HPV vaccine continues to fall below target rates.
What Does the Future Hold for Vaccines?
Increasing Awareness and Utilization of Cancer Preventing Vaccine
Human papillomavirus (HPV) is the most common sexually transmitted virus in the United States—so common that nearly every sexually active person will acquire it at some point in his or her life. When not cleared by one’s immune system, certain strains of the virus are linked to serious health issues including genital warts and numerous types of cancer.